STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose Ranges (STELLAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00654537
Recruitment Status : Completed
First Posted : April 8, 2008
Last Update Posted : March 16, 2009
Information provided by:

Brief Summary:
To compare the efficacy of various doses of rosuvastatin with atorvastatin, pravastatin & simvastatin in reducing levels of low density lipoprotein cholesterol in subjects with hypercholesterolaemia.

Condition or disease Intervention/treatment Phase
Hypercholesterolemia Drug: Rosuvastatin Drug: Atorvastatin Drug: Pravastatin Drug: Simvastatin Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 5625 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 6 Week Open Label, Dose Comparison Study to Evaluate the Safety and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Subjects With Hypercholesterolemia.
Study Start Date : April 2001
Study Completion Date : October 2004

Arm Intervention/treatment
Experimental: 1
Drug: Rosuvastatin
Other Name: Crestor
Active Comparator: 2
Drug: Atorvastatin
Other Name: Lipitor
Active Comparator: 3
Drug: Pravastatin
Other Name: Lipostat
Active Comparator: 4
Drug: Simvastatin
Other Name: Zocor

Primary Outcome Measures :
  1. Percentage change in low density lipoprotein cholesterol. [ Time Frame: 4 & 6 weeks ]

Secondary Outcome Measures :
  1. Percentage change in other lipid parameters as defined by the protocol [ Time Frame: 6 weeks ]
  2. Safety evaluation [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Discontinuation of all previous lipid lowering therapy.
  • Fasting LDL-c levels of between 160mg/dl - 250 mg/dl at Visits 2 & 3 for subjects not on lipid lowering therapy at Visit 1.
  • Other lipid parameters as specified in the protocol.

Exclusion Criteria:

  • The use of lipid lowering drugs or dietary supplements after Visit 1.
  • Active arterial disease eg Unstable angina, or recent arterial surgery
  • Abnormal laboratory parameters as defined in the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00654537

Sponsors and Collaborators
Study Director: Eleanor Miller, MD AstraZeneca
Study Chair: Russell Esterline AstraZeneca

Responsible Party: Elisabeth Björk, AstraZeneca Identifier: NCT00654537     History of Changes
Other Study ID Numbers: 4522IL/0065
First Posted: April 8, 2008    Key Record Dates
Last Update Posted: March 16, 2009
Last Verified: March 2009

Keywords provided by AstraZeneca:
low density lipoproteins

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases
Atorvastatin Calcium
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors